The burgeoning landscape of treatment for excess body fat and type 2 diabetes is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant distinctions in their pharmacological profiles and

Arriving in the field of obesity therapy, retatrutide presents a distinct approach. Unlike many current medications, retatrutide functions as a twin agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) binding sites. The simultaneous s